ALPHA-1 ANTITRYPSIN DEFICIENCY

That this House is aware that Alpha-1 Antitrypsin Deficiency (Alpha-1) is a rare genetic disorder that most commonly results in lung and liver disease leading to significant disability and early mortality; understands that extensive expertise in Alpha-1 exists within the NHS but that there is considerable variation across the country in patient access to specialists and Alpha-1 therapy; notes that there is currently no care model within the NHS that provides integrated multi-disciplinary management for the unique needs of patients with this complex disease; and believes that this can be best addressed with the establishment of a nationally commissioned highly specialised service for Alpha-1.